Grand Slam wall may not derail Sun's offer to take Taro private, say analysts
This article was originally published in Scrip
Grand Slam Asset Management has opposed Sun Pharmaceutical Industries' sweetened offer price for the remaining 34% of Taro Pharmaceutical Industries not held by Sun in Taro, though some analysts say that it is unlikely to completely derail the Indian firm's plans based on Sun's voting might and potential backing of other minority shareholders.
You may also be interested in...
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.